IMRN
ImmuronยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IMRN Profile
Immuron Limited
An Australian developer of immunomodulator polyclonal antibodies that treats liver disease and infectious diseases
Pharmaceutical
--
06/09/2017
NASDAQ Stock Exchange
7
06-30
Depository Receipts (Ordinary Shares)
Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia
Focus on providing oral immunotherapy to humans using dairy-derived antibody products
Immuron Limited was established in 1994 under the laws of Australia. The Company is a commercial and clinical-stage biopharmaceutical company with a patented technology platform focused on the development and commercialization of a new class of specifically targeted polyclonal antibodies that the Company believes address serious unmet medical needs.
